Ipamorelin: What It Is, What Research Says, and Dosing
What Exactly Is Ipamorelin?
Your body makes growth hormone (GH) naturally, but production varies. Some researchers are interested in small molecules that can gently encourage the pituitary gland — the pea-sized gland at the base of your brain — to release more of it.
Ipamorelin is one of those molecules. It is a pentapeptide, meaning it is a tiny chain of just five amino acids (the building blocks of protein). Scientists classify it as a growth hormone secretagogue — a substance that signals the body to secrete, or release, GH.[3]
What made ipamorelin stand out from earlier compounds in its class? Selectivity. A landmark 1998 study found that, unlike related peptides such as GHRP-2 and GHRP-6, ipamorelin triggered GH release without significantly raising cortisol (the stress hormone) or ACTH (a hormone that can drive cortisol) — even at doses more than 200 times higher than needed for GH release.[3] That selectivity is why researchers called it "the first selective growth hormone secretagogue."[3]
How Does It Work?
Ipamorelin binds to a receptor in the brain and pituitary gland called the GHS-R1a receptor (growth hormone secretagogue receptor). Think of the receptor as a lock and ipamorelin as a key. When the key turns, the pituitary gets the signal to pump out GH.[3] That GH then triggers the liver to produce IGF-1 (insulin-like growth factor 1), which does much of the hands-on work in tissues like muscle and bone.[1]
What Is Research Studying It For?
Bone and Longitudinal Growth
A 1999 rat study gave ipamorelin to adult female rats for 15 days. The peptide dose-dependently increased the rate at which the rats' bones grew longer — from 42 micrometers per day in the control group up to 52 micrometers per day at the highest dose.[4] Body weight also increased with higher doses.[4] The authors noted that whether these effects would translate to children with growth problems would require future clinical studies.[4]
Muscle Support in Orthopaedics and Sports Medicine
Sports medicine and orthopaedic researchers have taken notice. A 2026 review in the American Journal of Sports Medicine highlighted that CJC-1295 combined with ipamorelin showed significantly improved muscle contractile force in mice that had lost muscle due to steroid use — though the authors stressed these findings are limited to animal models.[2] A separate 2026 orthopaedic review noted that GH secretagogues like ipamorelin activate IGF-1 signaling and satellite cell repair pathways, making them theoretically interesting for musculoskeletal recovery.[1]
Chemotherapy-Related Weight Loss
Cancer treatments like cisplatin often cause severe nausea and weight loss. A 2024 study used ferrets — an established animal model for nausea research — and found that ipamorelin helped prevent cisplatin-induced weight loss by approximately 24% during the delayed phase (48–72 hours after treatment).[5] This suggests possible future research directions in oncology supportive care, though human trials are still needed.
General Safety Profile in the Literature
A 2026 sports medicine review of peptide therapies noted that ipamorelin and related compounds are widely discussed in performance and recovery contexts, but emphasized that rigorous safety and efficacy data in humans remain scarce.[6] The same sentiment is echoed by orthopaedic researchers who call for well-designed clinical trials before any firm recommendations can be made.[2]
What the Evidence Does NOT Yet Show
It is important to be direct: most ipamorelin research is in animals, not humans. There are no large-scale, controlled human clinical trials establishing safe or effective doses for any condition. Orthopaedic and sports medicine reviewers in 2026 specifically stated that information on indications, dosing, frequency, and duration of treatment in humans "remains unknown."[2] This is not a small caveat — it is the central limitation of the field right now.
Where Does Dosing Research Stand?
Because no standard human dose has been established by clinical trials, any figures circulating online are extrapolated from animal studies or anecdotal reports. Our ipamorelin dosage chart compiles the dose ranges used across published research so you can see exactly what protocols scientists have tested — not what someone is recommending you do. If you want to explore dose ranges from the literature side by side, our calculator can help you compare them in one place.
The Bottom Line
Ipamorelin is a scientifically interesting peptide with a cleaner hormonal profile than earlier compounds in its class.[3] Animal research hints at roles in bone growth,[4] muscle preservation,[2] and countering treatment-related weight loss.[5] But the honest summary is: promising preclinical data, very little human evidence, and no established clinical dosing guidelines.[2] Research is ongoing, and this space is worth watching closely.
Sources
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026. PMID 41490200.
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine, 2026. PMID 41476424.
- Ipamorelin, the first selective growth hormone secretagogue. — European journal of endocrinology, 1998. PMID 9849822.
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. — Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 1999. PMID 10373343.
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. — Physiology & behavior, 2024. PMID 39043357.
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.), 2026. PMID 41966639.
EN
BR
ES
FR